Alzamend Neuro, Inc. (ALZN)
| Market Cap | 7.00M -5.2% |
| Revenue (ttm) | n/a |
| Net Income | -8.77M |
| EPS | -2.63 |
| Shares Out | 4.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,729 |
| Open | 1.380 |
| Previous Close | 1.370 |
| Day's Range | 1.380 - 1.460 |
| 52-Week Range | 0.840 - 2.680 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 9, 2026 |
About ALZN
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic ... [Read more]
Financial Performance
Financial StatementsNews
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tra...
Alzamend Neuro Annual report: Q4 2026
Alzamend Neuro has published its Q4 2026 annual report on July 22, 2026.
Alzamend Neuro Slides: Corporate presentation
Alzamend Neuro has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial
Alzamend Neuro (ALZN) announced “encouraging” pharmacodynamic findings from a brain magnetic resonance spectroscopy, or MRS, analysis conducted in six healthy human subjects in a trial conducted at Ma...
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact ...
Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001
Alzamend Neuro (ALZN) announced positive topline data from its first Phase II “Lithium in Brain” clinical trial in healthy human subjects, demonstrating that AL001 meets bioequivalence standards while...
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonate Superior Brain Penetration: AL001 showed numerically higher...
Alzamend Neuro Slides: Corporate presentation
Alzamend Neuro has posted slides in relation to its latest quarterly earnings report, which was published on March 26, 2026.
Alzamend Neuro initiates Phase II trial of AL001 study
Alzamend Neuro (ALZN) announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with BD type 1. The trial is being conducted at Massachusetts General Hospital…
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patients Topline data expected in third...
Alzamend Neuro Quarterly report: Q3 2026
Alzamend Neuro has published its Q3 2026 quarterly earnings report on March 11, 2026.
Alzamend Neuro Proxy statement: Proxy filing
Alzamend Neuro filed a proxy statement on February 26, 2026, providing details for shareholder voting and corporate governance matters.
Alzamend Neuro Proxy statement: Proxy filing
Alzamend Neuro filed a proxy statement on February 26, 2026, providing details for shareholder voting and corporate governance matters.
Alzamend Neuro Proxy statement: Proxy filing
Alzamend Neuro filed a proxy statement on February 9, 2026, providing details for shareholder voting and corporate governance matters.
Alzamend Neuro Quarterly report: Q2 2026
Alzamend Neuro has published its Q2 2026 quarterly earnings report on December 9, 2025.
Alzamend Neuro completes clinical portion of Phase II clinical study of AL001
Alzamend Neuro (ALZN) announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects. In collaboration with Massachusetts General Hospital as the...
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharma...
Alzamend Neuro Quarterly report: Q1 2026
Alzamend Neuro has published its Q1 2026 quarterly earnings report on September 10, 2025.
Alzamend Neuro to present at Military Health System Research Symposium
Alzamend Neuro (ALZN) will have a poster presentation at the Military Health System Research Symposium, being held from August 4-7, 2025, in Orlando, Florida. Title: Quantitate Differences in Lithium ...
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD ...
Alzamend Neuro reports FY25 net cash provided by financing activities of $10.4M
Alzamend Neuro (ALZN) reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with…
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alza...
Alzamend Neuro Annual report: Q4 2025
Alzamend Neuro has published its Q4 2025 annual report on July 22, 2025.
Alzamend Neuro Earnings release: Q4 2025
Alzamend Neuro released its Q4 2025 earnings on July 22, 2025, summarizing the period's financial results.
Alzamend Neuro announces final closing of $5M private placement
Alzamend Neuro (ALZN) has completed the final closing of its $5 million private placement. As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreemen...